ESR1 and cancer: The ongoing TAILOR RT by the Canadian Cancer Trials Group (NCT03488693) is expected to evaluate the benefit of RNI in biologically low-risk (ER-positive, HER2 negative, and Oncotype DX RS ≤25) breast cancer patients with one to three positive macroscopic nodes.